F. S. Sevryukov, E. Borodavina, Р. А. Isaev, V. Polkin, А. А. Ilyin, S. Vasilkov, Yury Panaseykin, D. N. Derbugov, S. A. Ivanov, S. Podvyaznikov, А. Kaprin
{"title":"Side skin reactions of multikinase inhibitors in treatment of thyroid cancer","authors":"F. S. Sevryukov, E. Borodavina, Р. А. Isaev, V. Polkin, А. А. Ilyin, S. Vasilkov, Yury Panaseykin, D. N. Derbugov, S. A. Ivanov, S. Podvyaznikov, А. Kaprin","doi":"10.17650/2222-1468-2020-10-4-44-49","DOIUrl":null,"url":null,"abstract":"Dermal toxicity of anti-cancer drugs apparent in patients with thyroid cancer. This side effect appears, in particular, in relation to increased administration of targeted anti-cancer treatment, especially tyrosinkinase inhibitors, towards various receptors of growth factors which are applied in the ethiopathogenesis of a tumor cell. Our article focuses on the dermatotoxity, designated also as skin reaction, which most frequently occurs in patients treated by tyrosinkinase inhibitors – sorafenib, vandetonib, cabozantinib and lenvantinib. High prevalence of dermatotoxity, reported by patients, treated with these drugs underscores the need for greater understanding of the pathogenesis and management of this syndrome.","PeriodicalId":36598,"journal":{"name":"Opuholi Golovy i Sei","volume":"40 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Opuholi Golovy i Sei","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/2222-1468-2020-10-4-44-49","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Dermal toxicity of anti-cancer drugs apparent in patients with thyroid cancer. This side effect appears, in particular, in relation to increased administration of targeted anti-cancer treatment, especially tyrosinkinase inhibitors, towards various receptors of growth factors which are applied in the ethiopathogenesis of a tumor cell. Our article focuses on the dermatotoxity, designated also as skin reaction, which most frequently occurs in patients treated by tyrosinkinase inhibitors – sorafenib, vandetonib, cabozantinib and lenvantinib. High prevalence of dermatotoxity, reported by patients, treated with these drugs underscores the need for greater understanding of the pathogenesis and management of this syndrome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
